Nuclear Medicine and Biology
Volume 33, Issue 6 , Pages 723-733 , August 2006

Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues

  • Yubin Miao

      Affiliations

    • Department of Internal Medicine, University of Missouri-Columbia, Columbia, MO 65211, USA
    • Department of Dermatology, University of Missouri-Columbia, Columbia, MO 65211, USA
    • Harry S. Truman Memorial Veteran Hospital, Columbia, MO 65201, USA
    • Corresponding Author InformationCorresponding author. Departments of Internal Medicine and Dermatology, A051 VA Research Service, University of Missouri-Columbia, Columbia, MO 65211, USA. Tel.: +1 573 814 6000x3681; fax: +1 573 814 6551.
    • Current address: 2502 Marble NE, MSC09 5360, College of Pharmacy, 1 University of New Mexico, Albuquerque, NM 87131-0001, USA. Tel.: +1 505 925 4437; fax: +1 505 272 6749.
    • ,
  • Darrell R. Fisher

      Affiliations

    • Pacific Northwest National Laboratory, Richland, WA 99352, USA
    • ,
  • Thomas P. Quinn

      Affiliations

    • Harry S. Truman Memorial Veteran Hospital, Columbia, MO 65201, USA
    • Department of Biochemistry, University of Missouri-Columbia, Columbia, MO 65211, USA
    • Department of Radiology, University of Missouri-Columbia, Columbia, MO 65211, USA

Received 2 May 2006 ,Revised 2 June 2006 ,Accepted 15 June 2006.

References 

  1. Lewis JS, Lewis MR, Cutler PD, Srinivasan A, Schmidt MA, Schwarz SW, et al. Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. Clin Cancer Res. 1999;5:3608–3616
  2. Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, et al. Receptor mediated radiotherapy with 90Y-DOTA-d-Phe1-Tyr3-octreotide. Eur J Nucl Med. 2001;28:426–434
  3. De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WAP, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002;32:133–140
  4. Miao Y, Owen NK, Fisher DR, Hoffman TJ, Quinn TP. Therapeutic efficacy of a 188Re labeled α-melanocyte stimulating hormone peptide analogue in murine and human melanoma-bearing mouse models. J Nucl Med. 2005;46:121–129
  5. Volkert WA, Goeckeler WF, Ehrhardt GJ, Ketring AR. Therapeutic radionuclides: production and decay property consideration. J Nucl Med. 1991;32:174–185
  6. Mørgenson CE, Sølling K. Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest. 1977;37:477–486
  7. Silbernagl S. The renal handling of amino acids and oligopeptides. Physiol Rev. 1988;68:912–986
  8. Maack T, Johnson V, Kan ST, Figueiredo J, Sigulem D. Renal filtration, transport, and metabolism of low molecular weight proteins: a review. Kidney Int. 1979;16:251–270
  9. Bass LA, Lanahan MV, Duncan JR, Erion JL, Srinivasan A, Schmidt MA, et al. Identification of the soluble in vivo metabolites of indium-111-diethylenetriaminepentaacetic acid-d-Phe1-octreotide. Bioconjug Chem. 1998;9:192–200
  10. Duncan JR, Welch MJ. Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J Nucl Med. 1993;34:1728–1738
  11. Franano FN, Edwards WB, Welch MJ, Duncan JR. Metabolism of receptor targeted 111In-DTPA-glycoproteins: identification of 111In-DTPA-ε-lysine as the primary metabolic and excretory product. Nucl Med Biol. 1994;21:1023–1034
  12. Rogers BE, Franano FN, Duncan JR, Edwards WB, Anderson CJ, Connett JM, et al. Identification of metabolites of 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo. Cancer Res (suppl). 1995;55:5714s–5720s
  13. Arano Y, Fujioka Y, Akizawa H, Ono M, Uehara T, Wakisaka K, et al. Chemical design of radiolabeled antibody fragments for low renal radioactivity levels. Cancer Res. 1999;59:128–134
  14. Kobayashi H, Le N, Kim IS, Kim M-K, Pie J-E, Drumm D, et al. The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points. Cancer Res. 1999;59:422–430
  15. Behr TM, Sharkey RM, Juweid ME, Blumenthal RD, Dunn RM, Bair HJ, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res. 1995;55:3825–3834
  16. Behr TM, Becker WS, Sharkey RM, Juweid ME, Dunn RM, Bair HJ, et al. Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J Nucl Med. 1996;37:829–833
  17. Bernard BF, Krenning EP, Breeman WAP, Rolleman EJ, Bakker WH, Visser TJ, et al. d-Lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med. 1997;38:1929–1933
  18. Rolleman EJ, Valkema R, De Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30:9–15
  19. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol. 2001;19:3622–3634
  20. Giblin MF, Wang NN, Hoffman TJ, Jurisson SS, Quinn TP. Design and characterization of α-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci U S A. 1998;95:12814–12818
  21. Chen J, Cheng Z, Hoffman TJ, Jurisson SS, Quinn TP. Melanoma-targeting properties of 99mtechnetium-labeled cyclic α-melanocyte-stimulating hormone peptide analogues. Cancer Res. 2000;60:5649–5658
  22. Miao Y, Owen NK, Whitener D, Gallazzi F, Hoffman TJ, Quinn TP. In vivo evaluation of 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer. 2002;101:480–487
  23. Miao Y, Whitener D, Feng W, Owen NK, Chen J, Quinn TP. Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. Bioconjug Chem. 2003;14:1177–1184
  24. Chen J, Cheng Z, Owen NK, Hoffman TJ, Miao Y, Jurisson SS, et al. Evaluation of an 111In-DOTA-rhenium cyclized α-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties. J Nucl Med. 2001;42:1847–1855
  25. Cheng Z, Chen J, Miao Y, Owen NK, Quinn TP, Jurisson SS. Modification of the structure of a metallopeptide: synthesis and biological evaluation of 111In-labeled DOTA-conjugated rhenium-cyclized α-MSH analogues. J Med Chem. 2002;45:3048–3056
  26. Miao Y, Hoffman TJ, Quinn TP. Tumor targeting properties of 90Y and 177Lu labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model. Nucl Med Biol. 2005;32:485–493
  27. Schubiger PA, Alberto R, Smith A. Vehicles, chelators, and radionuclides: choosing the “building blocks” of an effective therapeutic radioimmunoconjugate. Bioconjug Chem. 1996;7:165–179
  28. Stolz B, Weckbecker G, Smith-Jones PM, Albert R, Raulf F, Bruns C. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-dPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA20948 tumors. Eur J Nucl Med. 1998;25:668–674
  29. Hnatowich DJ, Virzi F, Doherty PW. DTPA-coupled antibodies labeled with yttrium-90. J Nucl Med. 1985;26:503–509
  30. Hui TE, Fisher DR, Kuhn JA, Williams LE, Nourigat C, Badger CC, et al. A mouse model for calculating cross-organ beta doses from yttrium-90-labeled immunoconjugates. Cancer. 1994;73(Suppl):951–957
  31. Beatty BG, Kuhn JA, Hui TE, Fisher DR, Williams LE, Beatty JD. Application of the cross-organ beta dose method for tissue dosimetry in tumor-bearing mice treated with a 90Y-labeled immunoconjugate. Cancer. 1994;73(Suppl):958–965
  32. Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov. 2004;3:488–499
  33. Béhé M, Kluge G, Becker W, Gotthardt M, Behr TM. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med. 2005;46:1012–1015
  34. Rolleman EJ, Krenning EP, Van Gameren A, Bernard BF, De Jong M. Uptake of [111In-DTPA0]octreotide in the rat kidney is inhibited by colchicine and not by fructose. J Nucl Med. 2004;45:709–713
  35. De Jong M, Barone R, Krenning EP, Bernard BF, Melis M, Vissor T, et al. Megalin is essential for renal proximal tubule reabsorption of 111In-DTPA-octreotide. J Nucl Med. 2005;46:1696–1700
  36. Rösch F, Herzog H, Stolze B, Brockmann J, Köhle M, Mühlensiepen H, et al. Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-dPhe1-Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in nonhuman primates and calculation of radiation doses of the 90Y-labeled analogue. Eur J Nucl Med. 1999;26:358–366
  37. McQuade P, Miao Y, Yoo J, Quinn TP, Welch MJ, Lewis JS. Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of α-MSH. J Med Chem. 2005;48:2985–2992
  38. Miao Y, Hylarides M, Fisher DR, Shelton T, Moore H, Wester DW, et al. Melanoma therapy via peptide-targeted α-radiation. Clin Cancer Res. 2005;11:5616–5621
  39. De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WAP, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002;32:133–140

PII: S0969-8051(06)00106-5

doi: 10.1016/j.nucmedbio.2006.06.005

Nuclear Medicine and Biology
Volume 33, Issue 6 , Pages 723-733 , August 2006

Article Tools

* Image Usage & Resolution